BWX Technologies: Robust Q2 And Upgraded Outlook Reinforce Buy Thesis

BWX Technologies (BWXT) reported robust Q2 2025 results, exceeding forecasts with $764 million in revenue (+12% YoY) and a record $6 billion order book (+70% YoY), driven by significant US Navy contracts and accelerated commercial growth following the Kinectrics acquisition. The company raised its full-year adjusted EPS guidance to $3.65-$3.75, validating its diversification strategy and leading analysts to maintain a 'Buy' rating with a $186 target price, as elevated valuation multiples are seen as justified by stable defense cash flow and high commercial growth potential.

Analysis

BWX Technologies (BWXT) demonstrated strong performance in its second quarter of 2025, validating its strategy of leveraging a stable defense business to fuel commercial expansion. The company surpassed forecasts with revenue of $764 million, a 12% year-over-year increase, driven by growth in both its Government Operations (+9% YoY to $589 million) and Commercial Operations (+24% YoY to $176 million). This growth was underpinned by the acquisition of Kinectrics, increased demand for fleet nuclear components, and higher sales of medical isotopes. A key indicator of future performance is the record order backlog, which swelled 70% YoY to $6 billion, representing nearly two years of revenue and providing significant visibility. Consequently, management raised its full-year 2025 adjusted EPS guidance to $3.65–$3.75. While the company's valuation multiples are elevated, with a forward P/E of 45x, this premium is attributed to the predictable cash flow from its government contracts, which constitute 76% of revenue, and the unique growth trajectory of its commercial business, which is projected to grow 50% YoY. The company also maintains a shareholder-friendly capital return policy, with a stable dividend and a history of share buybacks.

Key Decisions for Investors

• Investors should view BWXT's elevated valuation in the context of its dual-growth profile, where stable, long-term defense contracts provide a foundation for high-margin commercial expansion in nuclear services and medicine.
• It is critical to monitor execution on the company's large, fixed-price contracts, as any cost overruns or delays represent a primary risk to margin stability despite the strong revenue visibility from the record backlog.
• Consider the potential for further upside, as management's upgraded guidance may be conservative, leaving room for positive surprises from new contract options or accelerated growth in emerging markets like Small Modular Reactors (SMRs).
• Factor in the potential for enhanced shareholder returns, as the modest dividend yield is supported by a low payout ratio, and the share buyback program may resume following the recent pause for the Kinectrics acquisition.